Susanne M. Arnold, MD | UK Healthcare

Dr. Susanne Arnold, MD

Claim this profile

University of Kentucky/Markey Cancer Center

Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
39 reported clinical trials
76 drugs studied

Area of expertise

1Lung Cancer
Global Leader
Susanne Arnold, MD has run 16 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Non-Small Cell Lung Cancer
Global Leader
Susanne Arnold, MD has run 14 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
RET positive

Affiliated Hospitals

Image of trial facility.
University Of Kentucky/Markey Cancer Center
Image of trial facility.
University Of Kentucky

Clinical Trials Susanne Arnold, MD is currently running

Image of trial facility.

EP0031

for Cancer

The aim of this study is to assess the safety, side effects and effectiveness of EP0031 in patients with advanced RET-altered malignancies (NSCLC)
Recruiting1 award Phase 1 & 2
Image of trial facility.

Pembrolizumab + Radiation vs Chemotherapy + Radiation

for Head and Neck Cancer

This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or patients with a second head and neck cancer that is not from metastasis (primary). Radiation therapy uses high energy radiation or protons to kill tumor cells and shrink tumors. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Carboplatin is also in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab alone after surgery may work better than the usual approach in shrinking recurrent or primary head and neck squamous cell carcinoma.
Recruiting1 award Phase 231 criteria

More about Susanne Arnold, MD

Clinical Trial Related3 years of experience running clinical trials · Led 39 trials as a Principal Investigator · 16 Active Clinical Trials
Treatments Susanne Arnold, MD has experience with
  • Pembrolizumab
  • Cisplatin
  • Ipatasertib
  • Binimetinib
  • Paclitaxel
  • Carboplatin

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Susanne Arnold, MD specialize in?
Is Susanne Arnold, MD currently recruiting for clinical trials?
Are there any treatments that Susanne Arnold, MD has studied deeply?
What is the best way to schedule an appointment with Susanne Arnold, MD?
What is the office address of Susanne Arnold, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security